gesunheitpfleges.org



CPRIT awards Bellicum $5.7 million to advance CaspaCIDe therapy for late stage cancer

February 22, 2016

The award will support clinical development of CaspaCIDe??, Bellicum's solution to the problem of Graft versus Host Disease (GvHD), a debilitating and often fatal side effect of bone marrow transplantation. Originally developed by Bellicum CSO Dr. David Spencer, Vice Chair of Pathology and Immunology at Baylor College of Medicine, and advanced into clinical trials by Dr. Malcolm Brenner, Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, CaspaCIDe?? works by allowing the transplant physician to selectively eliminate transplanted cells that cause GvHD. Building on promising early clinical results seen in Dr. Brenner's "CASPALLO" trial, the CPRIT award will support the execution of a randomized, double-blind clinical trial in patients with high risk hematologic malignancies.

"For cancer patients with high risk leukemias and lymphomas, a bone marrow transplant offers a chance of a cure, but mortality from the procedure is high," stated Bellicum Founder, Chairman and CMO Dr. Kevin Slawin. "In this application, CaspaCIDe?? provides a rapid and effective means to resolve GvHD, the number one problem facing transplant patients and their physicians today.  More broadly, it has the potential to transform medicine by enabling a wide range of new, safer, more effective cell therapies."

SOURCE Bellicum Pharmaceuticals, Inc.